FDA TEMPO Pilot — Pre-Authorization Pathway for Generative AI Medical Devices (2026)
CONCEPTThe FDA TEMPO (Total Product Life Cycle Advisory for Modular and Open Devices) pilot program creates a pre-authorization pathway for generative AI medical devices, enabling developers to bring AI-enabled tools to patients before completing full FDA authorization. The pilot represents a regulatory innovation: instead of requiring complete validation before market entry, TEMPO allows conditional authorization with post-market surveillance and iterative validation. This balances innovation speed with safety requirements. Key features include: expedited review for certain AI device categories; conditional authorization with ongoing monitoring; and structured feedback mechanisms between FDA and developers. The program aims to reduce time-to-market for AI medical devices while maintaining safety oversight. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.